Who are 131-I-TM-601's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Treatment Choice (TC), TAK-667, MB-102 DMID, SCTB14, KI1106 4g, QD, RNF.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/131-i-tm-601.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

131-I-TM-601 — Competitive Intelligence Brief

131-I-TM-601 (131-I-TM-601) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Targeted alpha-particle therapy. Area: Oncology.

phase 2 Targeted alpha-particle therapy CD47 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

131-I-TM-601 (131-I-TM-601) — TransMolecular. 131-I-TM-601 is a targeted alpha-particle therapy that selectively targets and destroys cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
131-I-TM-601 TARGET	131-I-TM-601	TransMolecular	phase 2	Targeted alpha-particle therapy	CD47
Treatment Choice (TC)	Treatment Choice (TC)	Astex Pharmaceuticals, Inc.	phase 3	SIRPα inhibitor	CD47
TAK-667	TAK-667	Takeda	phase 3	CD47 antibody	CD47
MB-102 DMID	MB-102 DMID	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	monoclonal antibody	CD47
SCTB14	SCTB14	Sinocelltech Ltd.	phase 3	CD47/SIRPα axis inhibitor	CD47/SIRPα axis
KI1106 4g, QD	KI1106 4g, QD	Kuhnil Pharmaceutical Co., Ltd.	phase 3	CD47/SIRPα inhibitor	CD47/SIRPα axis
RNF	RNF	Merck KGaA, Darmstadt, Germany	phase 3	CD47/SIRPα inhibitor	CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Targeted alpha-particle therapy class)

TransMolecular · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 131-I-TM-601 — Competitive Intelligence Brief. https://druglandscape.com/ci/131-i-tm-601. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab